Position in SCLX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$18,244
+$17,592 QoQ
Shares Held
2,339
+1389.8% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#14
of 72 holders
Holding Since
Mar 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SCLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026OSAIC HOLDINGS, INC. holds $1,335,655,235 across 20 Drug Manufacturers - General names. SCLX ranks #18 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
359,552 | $431,257,490 | |
| 2 | JNJ |
Johnson & Johnson
|
958,469 | $243,422,370 | |
| 3 | ABBV |
AbbVie Inc.
|
855,570 | $215,295,632 | |
| 4 | MRK |
Merck & Co., Inc.
|
890,015 | $114,366,926 | |
| 5 | AMGN |
Amgen Inc
|
278,608 | $100,889,527 | |
| 6 | PFE |
Pfizer Inc
|
2,661,858 | $64,097,538 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
850,792 | $49,022,633 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
252,547 | $31,906,785 |
All Filings in SCLX
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18,244 | 2,339 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $652 | 98 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $14,005 | 1,148 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $4,545 | 231 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,365 | 232 | Shares | Defined | 2025-09-04 | |
| 2025-03-31 | $453 | 1,821 | Shares | Defined | 2025-05-12 | |
| 2024-12-31 | $0 | 2 | Shares | Defined | 2025-06-06 | |
| 2024-03-31 | $9 | 6 | Shares | Defined | 2024-05-10 | |
| 2023-09-30 | $889 | 635 | Shares | Defined | 2023-11-13 | |
| 2023-06-30 | $11,149 | 2,002 | Shares | Defined | 2023-08-21 | |
| 2023-03-31 | $8,380 | 1,022 | Shares | Defined | 2023-05-12 | |
| No filing history on record for this holder in this stock. | ||||||